1. Background
2. Objectives
3. Methods
3.1. Materials
3.2. Patients’ Specimens
3.3. Helicobacter pylori Culture
3.4. Cell Culture
3.5. Reverse Transcription and Real-time PCR
aTm: Annealing temperature.
bLength: The length of the amplified product via RT-PCR.
3.6. Construction of Expression Plasmid
3.7. Expression and Purification of Recombinant HapA Fusion Protein
3.8. CD4+T-Cell Immunopurification
3.9. HpaA Stimulation of IL-21 Secretion from CD4+ T Cells
3.10. Western Blotting
3.11. ELISA Analysis of Cytokines
3.12. Trans-Well Invasion Experiment
3.13. Statistical Analysis
4. Results
4.1. Lower levels of IL-21, MMP-2, and MMP-9 in Gastric Mucosa with Helicobacter pylori Infection Compared to After Radication
4.2. IL-21, MMP-2, and MMP-9 Expressions of mRNA Were Lower in Gastric Mucosa Tissues with Helicobacter pylori Radication Compared to Before Treatment
4.3. Expression and Identification of HapA Fusion Protein
The expression, purification, and identification of recombinant HapA protein. (A) Analysis of expressed recombinant protein HpaA from Escherichia coli DE3 (BL21) by SDS-PAGE; M: protein marker; Lanes 1, 2, 3, 4 are the lysates of induced E. coli DE3 with IPTG at 1 h, 2 h, 3 h, and 4 h, respectively; Lane 5 is the lysate of induced E. coli DE3 without IPTG; (B) Analysis of purified recombinant protein HpaA by SDS-PAGE; M: protein marker; Lane 1: purified recombinant protein HpaA (the recombinant protein HpaA is indicated by red arrows in figures)
4.4. HpaA Can Improve the IL-21 Release via Induced CD4+T Cells in Vitro
The IL-21 levels of CD4+ T cells with different treatments. (A) Western blotting analysis of IL-21 expression in CD4+ T cells with different treatments; Lane 1: The levels of IL-21 and β-actin in CD4+T cells without treatment; Lane 2: The levels of IL-21 and β-actin in CD4+ T cells with Helicobacter. pylori treatment (CD4+ T co-cultured with H. pylori at MOI of 100 for 24 h); Lane 3: The IL-21 and β-actin levels of CD4+ T cells from gastric mucosa of patients with H. pylori infection; Lane 4 to lane 7: The IL-21 and β-actin levels of CD4+ T cells with recombinant HpaA protein (10 μg/mL) treatment at 3 h, 6 h, 12 h, and 24 h, respectively; Lane 8: The levels of IL-21 and β-actin in CD4+T cells with HpaA protein and aptamer HA6 co-treatment. (B) Detection and comparison of the concentration of IL-21 from CD4+T cells' culture supernatants with different treatments by ELISA; H. pylori treatment group: CD4+ T cells were co-cultured with H. pylori at an MOI of 100 for 24 h; HapA treatment group: CD4+ T cells were treated with HpaA protein (10 μg/mL) for 24 h; HapA/aptamer HA6 treatment group: CD4+ T cells were treated with HpaA protein (10 μg/mL) and aptamer HA6 (1 nM) for 24 h. a stands for Hp treatment groups vs. control group, P = 0.0176; b stands for HpaA treatment groups vs. control group, P = 0.0123; c stands for HpaA/Apatamer HA6 treatment groups vs. control group; P = 0.3639, no statistical significance.
4.5. The IL-21 Secretion of Adhesin HpaA-induced CD4+T-cells from Helicobacter pylori Promoted the Expression of MMP-2 and MMP-9 in AGS Cells
Western blotting analyses of MMP-2 and MMP-9 expressions in AGS cells with different treatments. Lane 1: AGS cells without treatment as the control; Lane 2: AGS cells treated with the IL-21 antibody (50 ng/ml) for 24 h; Lane 3: AGS cells pretreated with the IL-21 antibody (50 ng/ml) before adding the anti-IL-21 antibody (10 μg/ml) and then cultured for further 24 h; Lane 4: AGS cells co-cultured with adhesin HpaA (10 μg/mL)-stimulated CD4+ T cells for 24 h; Lane 5: AGS cells pre-co-cultured with adhesin HpaA (10 μg/mL)-stimulated CD4+ T cells before adding the anti-IL-21 antibody (10 μg/mL) and then cultured for further 24 h; The total proteins from AGS cells with different treatments were isolated for Western blotting analysis.
4.6. HpaA Promoted the Migration of AGS via IL-21 Secretion from CD4+T Cells by Trans-Well
Analysis of AGS cell migration with different treatments via Trans-well. The AGS cells were cultured in upper culture wells but lower culture wells were loaded with treatments. The number of AGS cells was counted on the bottom of the upper wells for migration assessment. a stands for the IL-21 treatment group vs. the control group (culture medium), P = 0.0309; b stands for the IL-21 and anti-IL-21 mcAb co-treatment group vs. the control group, P = 0.8919; c stands for the CD4+ T cells with HpaA treatment group vs. the control group, P = 0.0365; d stands for the CD4+ T cells with HpaA and anti-IL-21 mcAb co-treatment group vs. the control group, P = 0.2280; e stands for CD4+ T cells with the HpaA and aptamer HA6 co-treatment group vs. the control group, P = 0.3118; f stands for the CD4+ T cells with aptamer HA6 co-treatment group vs. the control group, P = 0.1695.







